Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Inclusion Criteria:

1. Healthy male or female subjects aged 20 to 50 years, inclusive, at the time of
informed consent.

2. Subjects must be in good health as determined by the Investigator based on detailed
medical history, physical examination, vital signs, clinical laboratory tests, ECGs
and other screening evaluations.

3. Ability to provide written informed consent and complying with all study requirements
and restrictions.

4. Is a non-smoker and non-tobacco user for a minimum of 6 months prior to screening

Exclusion Criteria:

1. History or current evidence of any clinically significant cardiac, endocrinologic,
hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic,
dermatologic, psychiatric, renal, or other major disease, as determined by the
Investigator

2. Previous treatment with any GH Releasing Hormone (GHRH) analog.

3. Participation in another clinical trial or treatment with an investigational agent
within 30 days or 5 half-lives, whichever is longer, prior to enrollment.

4. History of cancer within the past five years (excluding non-melanoma skin cancer).

5. History of alcohol or drug abuse or dependence within 12 months of screening as
determined by the Investigator.

6. Subjects with a body weight > 120 kg.